BeStock  
Stocks › Biotechnology › INCY

Incyte INCY

US equityMarket cap rank #824BiotechnologyCAR-T Therapy
$114.63 −$1.25 (-1.07%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $114.63 0.00%
Open$116.85
Prev close$115.87
Day range$114.28 – $117.51
Volume1.54M
Market cap$23.36B
P/E (TTM)58.5
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership101.1%+0.01 pts vs. prior quarter
Institutions holding1,168-5 vs. prior quarter
Insider trades (recent)33 buys / 17 sellsNet buying
Short interest5.22% of floatDays to cover 5.6 · as of 30 Oct 2026
Short-sale volume share22.5%5-day average of daily volume

Short-sale volume as % of daily volume

13%22%32%41%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$2.97M (11 inflow days, 9 outflow days).

Net flow by order size, last 20 sessions

−$3.7MSuper+$699.0KBig+$667.8KMid−$1.9MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 40.2% of shares outstanding.

Largest holders

  • Baker Bros. Advisors LP15.09%
  • BlackRock9.38%
  • Vanguard Capital Management, LLC5.98%
  • Dodge & Cox4.94%
  • State Street Global Advisors4.84%
  • Vanguard Portfolio Management, LLC3.81%
  • AQR Capital Management2.66%
  • Geode Capital Management, LLC2.40%

By investor type

  • Mutual Fund69.82%
  • Hedge Fund22.80%
  • Government Pension Fund3.33%
  • Public Company2.21%
  • Private Company1.37%
  • Sovereign Wealth Fund0.66%
  • Individual/Insider0.55%
  • VC/PE Fund0.21%

Reported short interest has risen from 4.63% to 5.22% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
BlackRock Mutual Fund 2026/Q4 +1,096,600 9.4%
Merrill Lynch, Pierce, Fenner & Smith Incorporated Private Company 2026/Q4 +775,774 0.5%
Jupiter Fund Management Plc Mutual Fund 2026/Q4 +727,973 0.6%
Allspring Global Investments, LLC Mutual Fund 2026/Q4 +646,890 0.4%
Bellevue Asset Management AG Mutual Fund 2026/Q4 +489,936 0.2%
AssetMark, Inc. Mutual Fund 2026/Q4 +477,256 0.3%
Deka Investment GmbH Mutual Fund 2026/Q4 +474,610 0.3%
Northern Trust Global Investments Mutual Fund 2026/Q4 +337,922 1.0%
Baker Bros. Advisors LP Hedge Fund 2026/Q3 +312,565 15.2%
Virginia Retirement System Government Pension Fund 2026/Q4 +299,014 0.4%
Franklin Resources Mutual Fund 2026/Q4 +286,732 0.4%
Pictet Asset Management Limited Mutual Fund 2026/Q4 +262,372 0.5%
Squarepoint OPS LLC Hedge Fund 2026/Q4 +256,462 0.1%
AQR Capital Management Hedge Fund 2026/Q4 +245,749 2.7%
American Century Investment Management Mutual Fund 2026/Q4 +245,153 0.3%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
5 Nov 2026 Steven Stein Executive VP, Head of Late-stage Development & Chief Medical Officer Derivative Exercise and Sale -240,193 $119.66 1,578
2 Nov 2026 Thomas Tray Principal Financial Officer, VP of Finance & Chief Accounting Officer Open Market Disposition -610 $118.96 8,056
14 Oct 2026 Pablo Cagnoni President and Global Head of R&D Derivative Exercise and Sale -2,642 $112.71 –
30 Sep 2026 Lee Heeson Executive VP & Head of Incyte International Sale to Issuer -463 $117.14 10,694
29 Sep 2026 Edmund Harrigan Independent Director Other Acquisition +206 $121.35 21,583
29 Sep 2026 Baker Bros. Advisors LP Other Acquisition +644 – 31,074,895
29 Sep 2026 Paul Clancy Independent Director Other Acquisition +203 $121.35 24,196
21 Sep 2026 David Gardner Chief Strategy Officer Sale to Issuer -920 $126.93 1,437
14 Sep 2026 Pablo Cagnoni President and Global Head of R&D Derivative Exercise and Sale -23,218 $120.50 –
24 Aug 2026 Soni Basi Executive Vice President Sale to Issuer -504 $129.72 5,245
18 Aug 2026 Pablo Cagnoni President and Global Head of R&D Open Market Disposition -10,801 $125.56 –
11 Aug 2026 Pablo Cagnoni President and Global Head of R&D Open Market Disposition -10,803 $120.04 10,801
4 Aug 2026 Pablo Cagnoni President and Global Head of R&D Open Market Disposition -10,640 $122.69 21,604
4 Aug 2026 Patrick Mayes Vice President of Biotherapeutic Research Derivative Exercise and Sale -2,207 $123.99 1,904
2 Aug 2026 Patrick Mayes Vice President of Biotherapeutic Research Derivative Exercise and Sale -45,767 $122.19 1,904
30 Jul 2026 Pablo Cagnoni President and Global Head of R&D Open Market Disposition -15,888 $119.70 32,244
30 Jul 2026 Patrick Mayes Vice President of Biotherapeutic Research Open Market Disposition -2,187 $119.41 1,904
22 Jul 2026 Michael Morrissey Executive VP & Head of Global Technical Operations Other Derivative Acquisition +6,426 $116.69 6,426
22 Jul 2026 Michael Morrissey Executive VP & Head of Global Technical Operations Other Derivative Acquisition +8,999 – 8,999
22 Jul 2026 Lee Heeson Executive VP & Head of Incyte International Other Derivative Acquisition +13,498 – 13,498

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 10,649,327 5.2% 5.6
15 Oct 2026 10,025,354 4.9% 5.3
30 Sep 2026 9,987,084 4.9% 6.1
15 Sep 2026 9,981,369 4.9% 7.3
31 Aug 2026 9,364,687 4.6% 7.7
14 Aug 2026 9,389,500 4.6% 6.7

Discussion

No comments yet — be the first to weigh in on INCY.

Sign in to join the discussion.

Scroll to Top